Are we repeating mistakes of the past? A review of the evidence for esketamine.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32456714.
- Also identified by DOI 10.1192/bjp.2020.89.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Esketamine has been licensed for 'treatment-resistant depression' in the USA, UK and Europe. Licensing trials did not establish efficacy: two trials were negative, one showed a statistically significant but clinically uncertain effect, and a flawed discontinuation trial was included, against Food and Drug Administration precedent. Safety signals - deaths, including suicides, and bladder damage - were minimised.
Medical subject headings
- Depressive Disorder, Treatment-Resistant
- Ketamine
- Suicide